When psychedelics were first studied more than 50 years ago, researchers noticed that they were useful in helping people explore a greater sense of self. Now, after a half-century hiatus, scientists are studying psychedelics like MDMA, psilocybin, and ketamine as treatment for depression, PTSD, anxiety, and other mental health conditions. So, what promise do they hold as therapeutics? Albert Garcia-Romeu, a researcher at John’s Hopkins University, joins Dr. Sanjay Gupta to talk about how psychedelics can alleviate mental suffering and what the path forward might look like.
In this episode of WORK, Erika sits down with Rishad Tobaccowala—futurist, author, and former Chief Growth Officer at Publicis Groupe—for a big-picture conversation about how…
Evan Feigenbaum from Carnegie Endowment for International Peace comments on the U.S. request to Australia about pre-committing its role in the event of U.S.-China going…
“It turns out that Trump can actually learn.” Trump “offered Russia a lot” and in return Putin “gave him nothing”, says political scientist Ian Bremmer.…